A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer

Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer mortality in the United States [1]. Despite the achievement of high response rates, improvements in survival with aggressive surgical debulking and use of platinum/taxane combination chemotherapy, the disease recurs in the majority of the patients [2].